Abstract: Apparatus and method for compiling and executing hybrid classical-quantum programs. For example, one embodiment of an apparatus comprises: a host processor to perform a partial compilation on hybrid quantum-classical source code to generate one or more sequential blocks of quantum operations; a quantum compiler accelerator to receive compilation work offloaded by the host processor including the one or more sequential blocks of quantum operations, the quantum compiler to perform optimization operations to optimize runtime execution of one or more of the quantum operations in view if a quantum accelerator architecture to generate optimized quantum operations; and a quantum execution accelerator having the quantum accelerator architecture to execute the optimized quantum operations to manipulate a state of one or more qubits, to measure a state of the one or more qubits, and to provide measurement data indicating the state to the host processor.

Abstract: Apparatus and method for measurement-free (MF) quantum error correction (QEC). For example, one embodiment of a method comprises: determining an error syndrome on a first subset of ancilla qubits of a quantum processor; decoding the error syndrome to produce decoded results on a second subset of ancilla qubits of the quantum processor; applying the decoded results to one or more system qubits; and unconditionally resetting the first subset and/or second subset of ancilla qubits to remove entropy and/or noise from the quantum system, wherein the operations of determining the error syndrome, decoding the error syndrome, applying the error syndrome, and unconditionally resetting the first and/or second subset of ancilla qubits are performed responsive to a qubit controller executing quantum control instructions provided from or derived from a script and without transmitting measurement data related to the error syndrome to a non-quantum computing device.

Abstract: Apparatus and method for measurement-free (MF) quantum error correction (QEC). For example, one embodiment of a method comprises: determining an error syndrome on a first subset of ancilla qubits of a quantum processor; decoding the error syndrome to produce decoded results on a second subset of ancilla qubits of the quantum processor; applying the decoded results to one or more system qubits; and unconditionally resetting the first subset and/or second subset of ancilla qubits to remove entropy and/or noise from the quantum system, wherein the operations of determining the error syndrome, decoding the error syndrome, applying the error syndrome, and unconditionally resetting the first and/or second subset of ancilla qubits are performed responsive to a qubit controller executing quantum control instructions provided from or derived from a script and without transmitting measurement data related to the error syndrome to a non-quantum computing device.

Abstract: Apparatus and method for actively mitigating coherent errors by modifying an original quantum circuit, inserting Clifford gate operations at intermediate stages. Embodiments of the apparatus and method may perform CGI statically, at the compiling stage, and/or dynamically, at the control processing stage. The insertion of Clifford gates takes advantage of the symmetries in a quantum circuit and actively cancels coherent errors, maintaining the quantum processor in a state as close as possible to the original tune-up environment.

Abstract: Apparatus and method for hardware-specific quantum circuit synthesis. For example, one embodiment of an apparatus comprises: one or more memory and/or storage devices to store quantum computation specifications and hardware-specific constraints associated with a quantum processor; and a quantum circuit synthesizer to generate a hardware-optimal quantum circuit based on the quantum computation specifications and the hardware-specific constraints.

Abstract: A method for treating flexible bags, comprising transporting, opening, filling and closing the bags in subsequent treatment stations in which the bags are transported in holding devices on several tracks from one treatment station to the next. In one embodiment of the present invention, the bags are transported in a continuous motion; during treatment, the respective treatment station is moved from its initial position synchronously with the motion of the bags; and after treatment, the respective treatment station is returned to its initial position.

Abstract: An apparatus for automated manufacturing of a foil sleeve from a foil section. The apparatus includes a cylindrical shaping pipe that is configured as two separate halves, whereby one half of the shaping pipe is movable perpendicular to the axis of the shaping pipe and the other shaping pipe half is stationary. A folding apparatus includes two folding sections that are movable to and from the shaping pipe. The folding sections are configured to independently surround at least a portion of the cylindrical shaping pipe. A stationary sealing apparatus is disposed within the shaping pipe together with a movable sealing apparatus disposed on the exterior of the shaping pipe collaborate to generate a longitudinal sealed seam for a foil sleeve. The stationary shaping pipe half can include with a recess that defines the location of the longitudinal sealed seam.

Abstract: An apparatus for manufacturing a circular bag is configured with two anvil half-sections that are movable relative to each other from an open position to a closed position. An ultrasonic sealing tool is provided that is movable towards and away from the anvil half-sections and configured to seal a lid portion to a sleeve portion of the circular bag. In the closed position, the anvil half-sections define an interior space which is at least as large as the exterior circumference of the circular bag to be manufactured.

Abstract: In a heat exchanger used especially as an exhaust heat exchanger, provision is made for tube sheets, the tubes of a tube bundle, and a housing to be shaped from stainless steel sheets. The tube sheets are formed as deep-drawn and stamped parts, each of which has a circumferential wall that projects outward beyond the ends of the tubes in the tube bundle. The walls are welded to the housing, and each of the walls is abutted by a diffuser.

Abstract: The invention relates to a process for the production of biologically active, dimeric TGF-.beta., to novel TGF-.beta.s and pharmaceutical compositions comprising it. TGF-.beta. produced by this process can be used in various therapeutic modalities.

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g.

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g.

Abstract: A heat exchanger assembly and method of making same are disclosed. A plurality of thin walled aluminum tubes are connected to a tube bottom. The tubes are first inserted into the tube support openings in the tube bottom with tube ends flush with a collecting space side of the tube bottom. The tube ends are then welded by a laser beam guided around the circumference of the respective tube ends.

Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.

Abstract: Novel compounds of the formula I ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, C.sub.1 -C.sub.4 alkyl or are linked to form C.sub.3 -C.sub.7 cycloalkyl and R.sup.3, R.sup.4 and R.sup.5 are the same or different and are hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy, OR.sup.6, SR.sup.6, halogen, NR.sup.7 R.sup.8, NO.sub.2, CN, CONR.sup.7 R.sup.8 or CO.sub.2 R.sup.9 wherein R.sup.6 is C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.10 aralkyl and R.sup.7, R.sup.8 and R.sup.9 are the same or different and are hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.10 aralkyl or R.sup.7 and R.sup.8 together with the nitrogen atom to which they are bound form 5 or 6 membered azacycloalkyl or oxazacycloalkyl; Arg is arginine ?NH--CH(CH.sub.2 CH.sub.2 CH.sub.2 NH--C(.dbd.NH)--NH.sub.2)--CO!; X is methine CH or nitrogen; n is an integer from 0 to 7; L is a peptide linker, and H is the carboxy terminal end of hirudin, and salts thereof, are provided.

Abstract: The process for the production of a dimeric, biologically active Transforming Growth Factor type .beta. (TGF-.beta.)-like protein or a salt thereof, comprising refolding the denatured monomeric form of the protein in the presence of a mild detergent that permits folding of the monomeric protein into a spatial conformation, which after dimerization, is the conformation associated with the biological activity, while retaining the monomeric protein in soluble form. Mild detergents include sulfobetaines, 3-(3-chlolamidopropyl)dimethylammonio-1-propanesulfonate, 3-(3-chlolamidopropyl)dimethylammonio-2-hydroxy-1-propane-sulfonate, digitonin, cholate and deoxycholate at a concentration of about 1 to 100 mM. Compositions containing a TGF-.beta.

Abstract: The invention relates to the field of genetic engineering and provides novel DNA molecules which comprise multifunctional origins of replication and/or a DNA sequence coding for the most abundant protein in the supernatant of cultures of Lactococcus Spec., named Major Secretion Product (MSP), for its signal peptide and/or the promoter of the MSP gene. The novel DNA molecules are used for the production of novel shuttle vectors for cloning of DNA in at least E. coli and Lactococcus spec. or novel vectors for the expression of homologous or heterologous genes and the production of secreted gene products in gram positive bacteria such as Lactococcus spec. and Bacillus Spec.

Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.

Abstract: The invention concerns polypeptides related to human immunoglobulin E binding factors (IgE-Bfs), mRNa, DNAs and hybrid vectors coding for said polypeptides, hosts containing said hydrid vectors, processes for the preparation of said polypepties, mRNAs, DNAs, hybrid vectors, and hosts. The polypeptides can be used for the prevention and/or the treatment of allergic diseases, and accordingly the invention concerns also pharmaceutical preparations containing them.

Abstract: A screw head on a container-closing machine has jaws that are pivotable on a holder to grasp a closure cap and hold the cap tightly so that the cap can be screwed onto a container. For pivoting the jaws, the jaws are connected to levers, which rest on an actuating cone that is displaceable coaxially in the holder. The actuating cone is integrally connected to a piston of a cylinder-piston unit, which is likewise disposed coaxially in the holder and the piston is operable by a controlled fuel supply.